Published in J Gastrointest Surg on June 10, 2008
Risk Factors for the Development of Diabetes Mellitus After Distal Pancreatectomy | NCT03030209
Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? J Gastrointest Surg (2009) 1.10
Management of mucinous cystic neoplasms of the pancreas. World J Gastroenterol (2010) 1.09
Relationship between fractional pancreatic beta cell area and fasting plasma glucose concentration in monkeys. Diabetologia (2009) 0.88
Pancreatic volumetric assessment as a predictor of new-onset diabetes following distal pancreatectomy. J Gastrointest Surg (2012) 0.83
Perioperative intensive insulin therapy using artificial endocrine pancreas in patients undergoing pancreatectomy. World J Gastroenterol (2009) 0.81
Endocrine Function Impairment After Distal Pancreatectomy: Incidence and Related Factors. World J Surg (2016) 0.79
Risk factors for pancreatogenic diabetes after pancreaticoduodenectomy. Korean J Hepatobiliary Pancreat Surg (2012) 0.79
Multiple Endocrine Neoplasia: Genetics and Clinical Management. Surg Oncol Clin N Am (2015) 0.77
Combined laparoscopic spleen-preserving distal pancreatectomy and islet autotransplantation for benign pancreatic neoplasm. World J Gastroenterol (2014) 0.76
Population-Level Incidence and Predictors of Surgically Induced Diabetes and Exocrine Insufficiency after Partial Pancreatic Resection. Perm J (2017) 0.75
Distal pancreatectomy with splenectomy for the management of splenic hilum metastasis in cytoreductive surgery of epithelial ovarian cancer. J Gynecol Oncol (2016) 0.75
Anterior Roux-en-Y Pancreatico-jejunostomy for Pancreatic Trauma. J Surg Tech Case Rep (2014) 0.75
Nutritional and Metabolic Derangements in Pancreatic Cancer and Pancreatic Resection. Nutrients (2017) 0.75
Does the pancreatic volume reduction rate using serial computed tomographic volumetry predict new onset diabetes after pancreaticoduodenectomy? Medicine (Baltimore) (2017) 0.75
Short- and long-term outcomes of laparoscopic organ-sparing resection in pancreatic neuroendocrine tumors: a single-center experience. Surg Endosc (2017) 0.75
Pyrido(2,3-d)pyrimidine antibacterial agents. 3. 8-Alkyl- and 8-vinyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)pyrido(2,3-d)pyrimidine-6-carboxylic acids and their derivatives. J Med Chem (1975) 8.52
Specific skin-reactive protein from culture filtrate of Mycobacterium bovis BCG. Infect Immun (1981) 2.65
Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res (2009) 2.36
Predicting performance on the American Board of Surgery qualifying and certifying examinations: a multi-institutional study. Arch Surg (2010) 2.36
A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery (2011) 2.11
Pancreatic-pleural fistula is best managed by early operative intervention. Surgery (2009) 2.03
Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab (2011) 1.83
Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg (2008) 1.73
Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery. Surgery (2007) 1.65
miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. Clin Cancer Res (2009) 1.62
Potential pitfalls in the diagnosis of phaeochromocytoma. Med J Aust (2005) 1.61
Laparoscopic surgery for cancer: a systematic review and a way forward. J Am Coll Surg (2010) 1.58
Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem (2006) 1.58
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. J Med Chem (1990) 1.56
Controversies in clinical pancreatology: management of acute idiopathic recurrent pancreatitis. Pancreas (2003) 1.56
A selective, Bayesian approach to intraoperative PTH monitoring. Ann Surg (2010) 1.56
Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol (2009) 1.53
Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res (2007) 1.52
Movement-related cortical potentials in writer's cramp. Ann Neurol (1995) 1.51
Pancreatic serous cystadenocarcinoma: a case report and review of the literature. J Gastrointest Surg (2009) 1.47
Management of pancreatic fistulas after pancreaticoduodenectomy: results in 437 consecutive patients. Arch Surg (2005) 1.47
Synthesis and structure--antibacterial activity relationships of 7-(3-amino-1-propynyl and 3-amino-1-propenyl)quinolones. Chem Pharm Bull (Tokyo) (1998) 1.44
Abnormal head MRI in a neurologically normal boy with hypomelanosis of Ito. Am J Med Genet (1996) 1.44
Helicobacter heilmannii associated erosive gastritis. Intern Med (1999) 1.41
Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett (2006) 1.41
Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas (2003) 1.40
Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer (2003) 1.39
Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer (2002) 1.39
The Relationship of Parathyroidectomy and Bisphosphonates With Fracture Risk in Primary Hyperparathyroidism: An Observational Study. Ann Intern Med (2016) 1.38
Fatality due to severe Salmonella enteritis associated with acute renal failure and septicemia. Intern Med (1997) 1.38
Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res (2005) 1.38
Role of pancreatic cancer-derived exosomes in salivary biomarker development. J Biol Chem (2013) 1.37
Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg (2006) 1.36
Systemic disease-induced salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer. PLoS One (2009) 1.35
Natural history of intraductal papillary mucinous neoplasms (IPMN): current evidence and implications for management. J Gastrointest Surg (2007) 1.34
Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery (2011) 1.32
Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol (2008) 1.32
Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg (2003) 1.30
Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome. J Pediatr (1988) 1.27
Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg (2007) 1.25
Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas (2005) 1.25
An algorithm informed by the parathyroid hormone level reduces hypocalcemic complications of thyroidectomy. World J Surg (2010) 1.24
Epidemiology, risk factors, and the promotion of pancreatic cancer: role of the stellate cell. J Gastroenterol Hepatol (2012) 1.23
PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun (2003) 1.22
American Thyroid Association statement on outpatient thyroidectomy. Thyroid (2013) 1.22
The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Gastroenterology (2011) 1.19
Phaeochromocytoma: current concepts. Med J Aust (2005) 1.18
Oxygen free radicals and lipid peroxidation in the pathogenesis of gastric mucosal lesions induced by indomethacin in rats. Relation to gastric hypermotility. Digestion (1991) 1.18
Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Biochim Biophys Acta (2011) 1.17
Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res (2005) 1.17
The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res (2005) 1.14
Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers. Pancreas (2008) 1.12
A xenograft nude mouse model for perineural invasion and recurrence in pancreatic cancer. Pancreas (2005) 1.12
Studies on fine structure and cytochemical properties of erythrophores in swordtail, Xiphophorus helleri, with special reference to their pigment granules (Pterinosomes). J Cell Biol (1965) 1.12
Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am J Pathol (2011) 1.11
The clinical significance of MAGEA3 expression in pancreatic cancer. Int J Cancer (2006) 1.11
The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg (2005) 1.11
Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery (2008) 1.11
Synovial fluid cytokines and proteinases as markers of temporomandibular joint disease. J Oral Maxillofac Surg (1998) 1.10
Early detection of sporadic pancreatic cancer: summative review. Pancreas (2015) 1.10
High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prev Res (Phila) (2013) 1.08
Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J Surg Res (2004) 1.07
VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg (2002) 1.07
Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci (1987) 1.06
Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth. Pancreas (2008) 1.06
Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells. Clin Exp Metastasis (2004) 1.05
Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia (2009) 1.05
Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas (2013) 1.05
18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med (2009) 1.05
Effect of reoperation on outcomes in papillary thyroid cancer. Surgery (2013) 1.04
Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis (2001) 1.04
VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery (2005) 1.04
Risk of advanced papillary thyroid cancer in obese patients. Arch Surg (2012) 1.04